NKTR
Nektar TherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.01B
P/E Ratio
—
EPS
$-7.93
Beta
1.15
52W High
$109.00
52W Low
$7.99
50-Day MA
$75.19
200-Day MA
$60.11
Dividend Yield
—
Profit Margin
-284.20%
Forward P/E
34.01
PEG Ratio
0.31
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Fundamentals
| Revenue (TTM) | $55.63M |
| Gross Profit (TTM) | $55.63M |
| EBITDA | $-123.91M |
| Operating Margin | -352.20% |
| Return on Equity | -53.60% |
| Return on Assets | -15.30% |
| Revenue/Share (TTM) | $2.85 |
| Book Value | $19.55 |
| Price-to-Book | 3.47 |
| Price-to-Sales (TTM) | 36.06 |
| EV/Revenue | 27.24 |
| EV/EBITDA | -6.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $33.79M |
| Float | $29.11M |
| % Insiders | 0.45% |
| % Institutions | 79.98% |
Historical Volatility
HV 10-Day
53.77%
HV 20-Day
43.79%
HV 30-Day
39.47%
HV 60-Day
59.41%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($153.25 target)
1
Strong Buy8
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026